Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Metastatic Breast Cancer Treatment Market size was valued at USD 22.46 billion in 2024 and is set to exceed USD 79.39 billion by 2037, registering over 10.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of metastatic breast cancer treatment is evaluated at USD 24.41 billion.
The increasing prevalence of breast cancer globally, along with the growing recurrence rate of breast cancer is expected to fuel the development of this market. The growth of the market can also be attributed to factors such as the increasing geriatric population and an increase in exposure to cancer risk factors linked to social and economic development. Cancer is currently the second leading cause of death worldwide. According to the Globocan report, global cancer burden is estimated to have risen to 19.3 million cases and 10 million cancer-related deaths in 2020. According to Globocan report 2020, the incidence rate of breast cancer was 5.20% which accounted for 2.26 million new cases globally with a mortality rate of 6.9%. Such increasing prevalence of breast cancer is expected to drive the growth of global metastatic breast cancer treatment market.
Metastatic Breast Cancer Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Prevalence of Breast Cancer
- Increasing Investment in R&D
Challenges
- Risk of Adverse Effects of Radiation Exposure
- Lack of Awareness
Metastatic Breast Cancer Treatment Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
10.2% |
|
Base Year Market Size (2024) |
USD 22.46 billion |
|
Forecast Year Market Size (2037) |
USD 79.39 billion |
|
Regional Scope |
|
Metastatic Breast Cancer Treatment Segmentation
The metastatic breast cancer treatment market is segmented based on treatment type into chemotherapy, radiation therapy, biologic, targeted therapy, breast surgery, and hormone therapy, out of which, chemotherapy and radiation therapy segment is anticipated to grab the largest share by the end of 2021 on account of its high level of specificity and lesser side-effects. Moreover, increasing government approval of new treatment & drugs globally is also projected to contribute to the growth of the segment during the forecast period.
Based on end-user, the hospital segment held the largest share in the global metastatic breast cancer treatment market on the back of increasing patient influx and increasing spending by the hospitals on breast cancer treatments.
Our in-depth analysis of the global market includes the following segments:
|
By Treatment Type |
|
|
By End-user |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Metastatic Breast Cancer Treatment Industry - Regional Synopsis
Asia Pacific industry is likely to account for largest revenue share by 2037, owing to increasing breast cancer prevalence, and rising geriatric population in the region.The market in the Asia Pacific industry is set to dominate majority revenue share by 2037, owing to increasing breast cancer prevalence, and rising geriatric population in the region. Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the growing healthcare investment, accompanied by the presence of leading healthcare service providers, and the increasing prevalence of cancer in the region. Along with this, the countries in North America such as the United States is promoting campaigns for breast cancer patients, which is also expected to contribute to the market growth in the region. According to the report published by the National Cancer Institute, in 2020, 1.8 million new cancer cases were registered in the United States. Such increasing rate of cancer is further expected to drive the demand for metastatic breast cancer treatment in the North American countries. Alternatively, the market in Europe is also anticipated to occupy a significant share in the global metastatic breast cancer treatment market on account of its proven success in terms of technology development and a high prevalence of breast cancer in the region. As per the analysis of the Globocan, 0.53 million new breast cancer cases were registered in the European Union, with 0.14 million deaths in 2020. Such growing number of deaths due to breast cancer is expected to increase the R&D activities to develop better treatment in the market.
Companies Dominating the Metastatic Breast Cancer Treatment Landscape
- F. Hoffmann-La Roche Ltd
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Company, Inc.
- AstraZeneca Plc.
- Novartis
- Bayer AG
- Pfizer Inc.
- Eli Lilly and Company
- Sun Pharmaceutical Industries Limited
- Johnson & Johnson
- GlaxoSmithKline plc.
- Report ID: 2998
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
Metastatic Breast Cancer Treatment Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
